<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39416373</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1016-1430</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Medical journal of the Islamic Republic of Iran</Title><ISOAbbreviation>Med J Islam Repub Iran</ISOAbbreviation></Journal><ArticleTitle>Investigating the Effectiveness of Melatonin in the Treatment of Critically Ill Patients with COVID-19 Hospitalized in the Intensive Care Unit: A Double-Blind Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>41</StartPage><MedlinePgn>41</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">41</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.47176/mjiri.38.41</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Melatonin, a tryptophan product, has anti-inflammatory and virucidal effects. A study evaluated whether melatonin is more effective than placebo in critically ill COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The present study used a double-blind, randomized clinical trial in patients with COVID-19 hospitalized in the intensive care unit of Rasool Akram Hospital, Tehran. Iran. Melatonin 10 mg and placebo were given to the patients at night before bed. Patients were randomly divided into 2 groups. The first group was given melatonin with a therapeutic dose of 10 mg daily, and the second group was given a placebo with the same dose of 10 mg daily. Patients received melatonin or placebo for 7 days.The chi-square or Fisher exact test was used to compare qualitative variables. The study analyzed the mean of the variables under investigation by conducting a 2-factor repeated measures analysis of variance at 3 different time intervals in those administered medication or placebo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The study analyzed 44 melatonin patients and 42 placebo groups. The mean intensive care unit (ICU) hospitalization days were 11.23 ± 4.73 days in the melatonin group and 11.90 ± 6.52 days in the placebo group (<i>P</i> = 0.582). The mean days of hospitalization in the melatonin group were 19.70 ± 8.77 days and 21.48 ± 10.85 days in the placebo group (<i>P</i> = 0.407). The mean oxygen saturation before and after discharge from ICU in the melatonin group was 81 ± 6.73%, 91.02 ± 1.17%, and in the placebo group, 83.36 ± 8.27%, 91.21 ± 1.26, respectively (<i>P</i> = 0.467 and <i>P</i> = 0.150).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Melatonin can significantly reduce inflammation and oxidative stress markers in patients, making it a promising therapeutic option for COVID-19 patients. Further research is needed to determine the optimal treatment dosage and duration. Nonetheless, these results offer a promising avenue for future research and clinical practice.</AbstractText><CopyrightInformation>© 2024 Iran University of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tirkan</LastName><ForeName>Atefe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine, Hazrat-e Rasool Medical complex, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eskandari</LastName><ForeName>Delaram</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, School of Medicine, Hazrat-e Rasool Medical complex, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roham</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, School of Medicine, Antimicrobial Resistance Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aloosh</LastName><ForeName>Oldooz</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, School of Medicine, Hazrat-e Rasool Medical Complex, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramim</LastName><ForeName>Tayeb</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Health Information Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshar</LastName><ForeName>Hale</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9181-0794</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, School of Medicine, Hazrat-e Rasool Medical Complex, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Med J Islam Repub Iran</MedlineTA><NlmUniqueID>8910777</NlmUniqueID><ISSNLinking>1016-1430</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Intensive Care Unit</Keyword><Keyword MajorTopicYN="N">Melatonin</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>4</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39416373</ArticleId><ArticleId IdType="pmc">PMC11480672</ArticleId><ArticleId IdType="doi">10.47176/mjiri.38.41</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reiter RJ, Abreu-Gonzalez P, Marik PE, Dominguez-Rodriguez A. Therapeutic algorithm for use of melatonin in patients with COVID-19. Front Med. 2020;7:226. doi: 10.3389/fmed.2020.00226.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00226</ArticleId><ArticleId IdType="pmc">PMC7242729</ArticleId><ArticleId IdType="pubmed">32574327</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Wang X, Ni L, Di X, Ma B, Niu S. et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. doi: 10.1016/j.lfs.2020.117583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117583</ArticleId><ArticleId IdType="pmc">PMC7102583</ArticleId><ArticleId IdType="pubmed">32217117</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G, Reiter RJ. Melatonin: roles in influenza, Covid‐19, and other viral infections. Reviews in medical virology. 2020;30(3):e2109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235470</ArticleId><ArticleId IdType="pubmed">32314850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleszczyński K, Slominski AT, Steinbrink K, Reiter RJ. Clinical trials for use of melatonin to fight against COVID-19 are urgently needed. Nutrients. 2020;12(9):2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551551</ArticleId><ArticleId IdType="pubmed">32847033</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleszczyński K, Zillikens D, Fischer TW. Melatonin enhances mitochondrial ATP synthesis, reduces reactive oxygen species formation, and mediates translocation of the nuclear erythroid 2‐related factor 2 resulting in activation of phase‐2 antioxidant enzymes (γ‐GCS, HO‐1, NQO 1) in ultraviolet radiation‐treated normal human epidermal keratinocytes (NHEK) J Pineal Res. 2016;61(2):187.</Citation><ArticleIdList><ArticleId IdType="pubmed">27117941</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs. 2001;10(3):467.</Citation><ArticleIdList><ArticleId IdType="pubmed">11227046</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem. 2002;2(2):167.</Citation><ArticleIdList><ArticleId IdType="pubmed">11899099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleszczyński K, Slominski AT, Steinbrink K, Reiter RJ. Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed. Nutrients. 2020;12(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551551</ArticleId><ArticleId IdType="pubmed">32847033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Wang X, Ni L, Di X, Ma B, Niu S. et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. doi: 10.1016/j.lfs.2020.117583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117583</ArticleId><ArticleId IdType="pmc">PMC7102583</ArticleId><ArticleId IdType="pubmed">32217117</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Missiry MA, El-Missiry ZMA, Othman AI. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. Eur J Pharmacol. 2020;882:173329. doi: 10.1016/j.ejphar.2020.173329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173329</ArticleId><ArticleId IdType="pmc">PMC7324339</ArticleId><ArticleId IdType="pubmed">32615182</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina-Carballo A, Palacios-López R, Jerez-Calero A, Augustín-Morales MC, Agil A, Muñoz-Hoyos A. et al. Protective Effect of Melatonin Administration against SARS-CoV-2 Infection: A Systematic Review. Curr Issues Mol Biol. 2021;44(1):31–45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929125</ArticleId><ArticleId IdType="pubmed">35723382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousavi SA, Heydari K, Mehravaran H, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A. et al. Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. J Med Virol. 2022;94(1):263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662261</ArticleId><ArticleId IdType="pubmed">34460132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameri A, Asadi MF, Kamali M, Vatankhah M, Ziaei A, Safa O. et al. Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the Intensive Care Unit: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021;22(1):194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938382</ArticleId><ArticleId IdType="pubmed">33685474</ArticleId></ArticleIdList></Reference><Reference><Citation>Hlutkin S, Zinchuk V. Effect of melatonin on the blood oxygen transport during hypothermia and rewarming in rats. Adv Med Sci. 2008;53(2):234.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930873</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G, Reiter RJ. Melatonin: Roles in influenza, Covid-19, and other viral infections. Rev Med Virol. 2020;30(3):e2109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235470</ArticleId><ArticleId IdType="pubmed">32314850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowska K, Małkiewicz MA, Siemiński M, Cubała WJ, Winklewski PJ, Mędrzycka-Dąbrowska WA. The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit - a clinical review. Sleep Med. 2020;69:127–134. doi: 10.1016/j.sleep.2020.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2020.01.019</ArticleId><ArticleId IdType="pubmed">32074506</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusco LI, Cruz P, Cangas A, González Rojas, Vigo DE, Cardinali DP. Efficacy of melatonin in non-intensive care unit patients with COVID-19 pneumonia and sleep dysregulation. Melatonin Research. 2021;4(1) doi: 10.32794/mr11250089.</Citation><ArticleIdList><ArticleId IdType="doi">10.32794/mr11250089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali DP, Brown GM, Pandi-Perumal SR. An urgent proposal for the immediate use of melatonin as an adjuvant to anti-SARS-CoV-2 vaccination. Melatonin Research. 2021;4(1):206.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>